Salivary Glycated Albumin
| Status: | Recruiting |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 9/27/2018 |
| Start Date: | August 24, 2017 |
| End Date: | August 15, 2019 |
| Contact: | Maka S Hedrington, MD |
| Email: | mhedrington@som.umaryland.edu |
| Phone: | 410-706-5623 |
Clinical Study of Salivary Glycated Albumin
(1) to determine whether the ratio of glycated albumin and total albumin in saliva is
equivalent to blood and (2) to investigate whether the non-invasive SmartAlbu portable
salivary sensor is as accurate as standard tests that measure glycosylated hemoglobin
(HbA1c).
equivalent to blood and (2) to investigate whether the non-invasive SmartAlbu portable
salivary sensor is as accurate as standard tests that measure glycosylated hemoglobin
(HbA1c).
Inclusion Criteria:
- 123 individuals with type 1 or type 2 diabetes
- 53 non diabetic controls
- Age: 18 to 80
- Body mass index >18.5kg / m2
Exclusion Criteria:
- Acute illness (within 7 days) - respiratory infection, fever above 38 °C, sinusitis
infection, severe allergies.
- Individuals with known sickle cell, pregnancy, hemoglobinopathies, renal failure
- Subjects unable to give voluntary informed consent
We found this trial at
1
site
University of Maryland As a globally-connected university offering a world-class education, the University of Maryland...
Click here to add this to my saved trials
